 |
38 Diseases |  |
16 Trials |
|
16 Trials |  |
377 News |  |
| «12345 |
- Myalept (metreleptin) / Novelion
Clinical protocol, Trial completion, Trial primary completion date: Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy (clinicaltrials.gov) - Feb 7, 2017
P2, N=23, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2016
- Myalept (metreleptin) / Novelion
Enrollment closed: Expanded Access Metreleptin Study (clinicaltrials.gov) - Feb 7, 2017
P2, N=11, Active, not recruiting, Sponsor: University of Michigan
Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2016 Enrolling by invitation --> Active, not recruiting
- Myalept (metreleptin) / Novelion
Trial primary completion date: Short-term Effects of Leptin in People With Lipodystrophy (clinicaltrials.gov) - Nov 4, 2016
P2, N=40, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrolling by invitation --> Active, not recruiting Trial primary completion date: Oct 2016 --> Oct 2017
- Myalept (metreleptin) / Novelion
Clinical protocol, Trial primary completion date: Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy (clinicaltrials.gov) - Aug 23, 2016
P2, N=23, Active, not recruiting, Sponsor: University of Michigan
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: May 2016 --> Nov 2016
- Myalept (metreleptin) / Novelion
Clinical protocol, New P2 trial: CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy (clinicaltrials.gov) - Jan 14, 2016
P2, N=15, Recruiting, Sponsor: University of Michigan
- Myalept (metreleptin) / Novelion
Clinical protocol, Enrollment closed, Trial primary completion date: Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy (clinicaltrials.gov) - Jan 11, 2016
P2, N=23, Active, not recruiting, Sponsor: University of Michigan
Trial primary completion date: May 2016 --> Nov 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> May 2016
- Myalept (metreleptin) / Novelion
Enrollment status: Expanded Access Metreleptin Study (clinicaltrials.gov) - Jan 11, 2016
P2, N=10, Enrolling by invitation, Sponsor: University of Michigan
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> May 2016 Recruiting --> Enrolling by invitation
- Myalept (metreleptin) / Novelion
Trial primary completion date: Short-term Effects of Leptin in People With Lipodystrophy (clinicaltrials.gov) - Nov 9, 2015
P2, N=40, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Enrolling by invitation Trial primary completion date: Oct 2015 --> Oct 2016
- Myalept (metreleptin) / Novelion
Enrollment change: Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy (clinicaltrials.gov) - Aug 24, 2015
P3, N=17, Enrolling by invitation, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Trial primary completion date: Oct 2015 --> Oct 2016 N=30 --> 17
- Myalept (metreleptin) / Novelion
Enrollment change, Trial termination, Trial primary completion date: Effects of Metreleptin in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jun 24, 2015
P1, N=7, Terminated, Sponsor: University of Texas Southwestern Medical Center
N=30 --> 17 N=15 --> 7 | Recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Jan 2013; Sponsor request
- | Myalept (metreleptin) / Novelion
Trial completion, Enrollment change, Trial primary completion date: Therapeutic Approaches to HAART-Induced Lipodystrophy (clinicaltrials.gov) - Jun 23, 2015
P2, N=23, Completed, Sponsor: University of Texas Southwestern Medical Center
N=15 --> 7 | Recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Jan 2013; Sponsor request Recruiting --> Completed | N=130 --> 23 | Trial primary completion date: Jan 2016 --> Sep 2014
- || Myalept (metreleptin) / Novelion
Trial initiation date: MEASuRE: Metreleptin Effectiveness And Safety Registry (clinicaltrials.gov) - Jun 18, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: Aegerion Pharmaceuticals, Inc.
Recruiting --> Completed | N=130 --> 23 | Trial primary completion date: Jan 2016 --> Sep 2014 Initiation date: Dec 2014 --> Jan 2016
- Myalept (metreleptin) / Novelion
Enrollment change: Short-term Effects of Leptin in People With Lipodystrophy (clinicaltrials.gov) - Jun 11, 2015
P2, N=40, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Initiation date: Dec 2014 --> Jan 2016 N=20 --> 40
- Myalept (metreleptin) / Novelion
Trial initiation date: An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy (clinicaltrials.gov) - May 2, 2015
P=N/A, N=41, Completed, Sponsor: Bristol-Myers Squibb
N=20 --> 40 Initiation date: Nov 2008 --> Mar 2009
- Myalept (metreleptin) / Novelion
New P2 trial: Expanded Access Metreleptin Study (clinicaltrials.gov) - Apr 2, 2015
P2, N=10, Recruiting, Sponsor: University of Michigan
- | Myalept (metreleptin) / Novelion
Trial completion: An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=41, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: Nov 2008 --> Mar 2009 Active, not recruiting --> Completed
- Myalept (metreleptin) / Novelion
Trial completion, Trial primary completion date: Leptin to Treat Lipodystrophy (clinicaltrials.gov) - Feb 23, 2015
P2, N=105, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Feb 2015
- Myalept (metreleptin) / Novelion
Trial primary completion date: Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance (clinicaltrials.gov) - Jan 26, 2015
P2, N=20, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Feb 2015 Trial primary completion date: Dec 2099 --> Jan 2030
- ||| Myalept (metreleptin) / Novelion
Clinical: MEASuRE: Metreleptin Effectiveness And Safety Registry (clinicaltrials.gov) - Dec 29, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: AstraZeneca
- | Myalept (metreleptin) / Novelion
Trial completion, Bariatric surgery: Trial of Leptin Administration After Roux-en-Y Gastric Bypass (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=34, Completed, Sponsor: Columbia University
Trial primary completion date: Dec 2099 --> Jan 2030 Active, not recruiting --> Completed
- Myalept (metreleptin) / Novelion
Enrollment change: Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy (clinicaltrials.gov) - Nov 24, 2014
P3, N=30, Enrolling by invitation, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed N=15 --> 30
- Myalept (metreleptin) / Novelion
New P3 trial: Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy (clinicaltrials.gov) - Oct 15, 2014
P3, N=27, Enrolling by invitation, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Myalept (metreleptin) / Novelion
New P3 trial: Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy (clinicaltrials.gov) - Oct 15, 2014
P3, N=15, Enrolling by invitation, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Myalept (metreleptin) / Novelion
Enrollment closed, Trial primary completion date: An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy (clinicaltrials.gov) - Jul 21, 2014
P=N/A, N=41, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=15 --> 30 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Oct 2014
- Myalept (metreleptin) / Novelion
Enrollment change: Leptin to Treat Lipodystrophy (clinicaltrials.gov) - Jul 4, 2014
P2, N=105, Active, not recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Oct 2014 N=99999999 --> 105
- Myalept (metreleptin) / Novelion
Enrollment closed, Enrollment change: Leptin to Treat Lipodystrophy (clinicaltrials.gov) - Jul 4, 2014
P2, N=105, Active, not recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
N=99999999 --> 105 Recruiting --> Active, not recruiting | N=99999999 --> 105
- Myalept (metreleptin) / Novelion
Enrollment change: Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance (clinicaltrials.gov) - Mar 18, 2014
P2, N=20, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Active, not recruiting | N=99999999 --> 105 N=99999999 --> 20
- | Myalept (metreleptin) / Novelion, pramlintide/metreleptin (AC137-164594) / BMS
Trial termination: A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects (clinicaltrials.gov) - Nov 13, 2013
P2, N=213, Terminated, Sponsor: Bristol-Myers Squibb
N=99999999 --> 20 Active, not recruiting --> Terminated; Results from previous study DFA102 demonstrated neutralizing activity to metreleptin in invitro assay in 2 participants.
- ||| Myalept (metreleptin) / Novelion
Enrollment change, Combination therapy: Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin (clinicaltrials.gov) - Nov 12, 2013
P2, N=274, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Terminated; Results from previous study DFA102 demonstrated neutralizing activity to metreleptin in invitro assay in 2 participants. N=400 --> 274
- |||| Myalept (metreleptin) / Novelion
Trial completion, Combination therapy: Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin (clinicaltrials.gov) - Nov 12, 2013
P2, N=274, Completed, Sponsor: Bristol-Myers Squibb
N=400 --> 274 Active, not recruiting --> Completed
- Myalept (metreleptin) / Novelion
Enrollment change: Short-term Effects of Leptin in People With Lipodystrophy (clinicaltrials.gov) - Nov 1, 2013
P2, N=20, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed N=40 --> 20
- Myalept (metreleptin) / Novelion
Enrollment change: An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy (clinicaltrials.gov) - Jul 11, 2013
P=N/A, N=50, Recruiting, Sponsor: Bristol-Myers Squibb
N=40 --> 20 N=30 --> 50
- Myalept (metreleptin) / Novelion
New P2 trial: Short-term Effects of Leptin in People With Lipodystrophy (clinicaltrials.gov) - Jan 27, 2013
P2, N=20, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Myalept (metreleptin) / Novelion
Clinical protocol, New P2 trial: Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy (clinicaltrials.gov) - Sep 3, 2012
P2, N=20, Recruiting, Sponsor: University of Michigan
- |||| Symlin (pramlintide) / AstraZeneca
Trial completion: Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects (clinicaltrials.gov) - Oct 3, 2011
P2, N=636, Completed, Sponsor: Bristol-Myers Squibb
N=30 --> 50 Active, not recruiting --> Completed
- Myalept (metreleptin) / Novelion
Enrollment closed: Leptin in Human Energy and Neuroendocrine Homeostasis (clinicaltrials.gov) - Sep 13, 2011
P=N/A, N=60, Active, not recruiting, Sponsor: Columbia University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting